Phase II Trial of Dual LAG-3–PD-1 Inhibition With Neoadjuvant Relatlimab + Nivolumab in Resectable Stage III Melanoma

June 4-8, 2021; Online at https://conferences.asco.org/am
Neoadjuvant relatlimab plus nivolumab produced high rates of pCR and MPR in patients with resectable stage III melanoma with a tolerable safety profile.
Format: Microsoft PowerPoint (.ppt)
File Size: 457 KB
Released: June 7, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD Released: June 28, 2022

AMBER trial of cobolimab and dostarlimab shows manageable safety in advanced solid tumors and promising activity in advanced melanoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 20, 2022

CheckMate 067 7.5-year follow-up with nivolumab + ipilimumab in advanced melanoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Data from the TRICOTEL study of the combination of atezolizumab, cobimetinib, and vemurafenib in advanced BRAFV600-mutated melanoma with CNS metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings